The Food and Drug Administration (FDA) has announced a nationwide recall of generic cetirizine hydrochloride antihistamine tablets, commonly used for allergy relief, after the detection of possible contamination with ranitidine, a heartburn medication. The recall was initiated by Unique Pharmaceutical Laboratories following quality concerns during production.
What Happened
On July 18, 2026, Unique Pharmaceutical Laboratories voluntarily recalled cetirizine hydrochloride tablets USP 5 mg after a pharmacy technician noticed discoloration and the presence of a red dot on some tablets during counting and bottling. The FDA confirmed that this indicated potential cross-contamination with ranitidine. The affected tablets were distributed nationwide by Rising Pharma Holdings Inc., packaged in 100-tablet bottles. The recalled products include specific lot numbers with an expiration date of October 2028.
Key Facts
The recalled products contain the following lot numbers: GY825029, GY825030, GY825031, and GY825032. The recall affects cetirizine tablets with a dosage strength of 5 mg. Unique Pharmaceutical Laboratories coordinated the recall after internal quality control alerted them to irregularities. There have been no reported adverse events linked to the affected tablets as of the FDA’s announcement.
What This Means
This recall highlights ongoing challenges in pharmaceutical manufacturing quality control, especially when multiple drugs are produced in the same facility. For consumers, exposure to ranitidine—especially those with hypersensitivity—can result in serious side effects such as hypotension, breathing difficulties, and even potentially life-threatening reactions. The recall underscores the importance of vigilance by both manufacturers and regulators to protect public health. Pharmacies and retailers must efficiently manage the returned inventory to prevent distribution of potentially contaminated medications.
Patients currently taking the recalled cetirizine tablets should consult their healthcare providers to assess any risk or need for alternative treatments. The incident may prompt healthcare professionals and consumers to monitor the supply chain more closely for safety and quality assurance.
Background
Ranitidine, the heartburn drug involved in the potential contamination, has been subject to regulatory scrutiny in recent years due to concerns about contaminants like NDMA. Although not directly related to this physical cross-contamination recall, this context has raised awareness about drug safety and manufacturing standards.
Cetirizine, marketed under brand-name labels such as Zyrtec, is a widely used over-the-counter antihistamine. The recalled version is a generic from Unique Pharmaceutical Laboratories, distributed through Rising Pharma Holdings.
What Comes Next
Rising Pharma Holdings has notified all affected customers and is arranging the return of all recalled products. Consumers with questions or concerns can contact Rising Pharma Holdings at 1-844-874-7464 or by email at pv@risingpharma.com or qa@risingpharma.com. Healthcare providers are advised to stay alert for potential reports of adverse reactions related to this recall.
Sources
This article is based on reporting and publicly available information from the following sources:
Read more Health & Public Health stories on Goka World News.